The use of instant technology, product development

ncycgdxhl · Wysłany: Wto 0:25, 15 Mar 2011

,[link widoczny dla zalogowanych]
The use of instant technology, product development

Solv follow-up products) to solve the durability problem of the first generation product,[link widoczny dla zalogowanych], and can use the standard tablet device, and Eurand's AdvaTab instant tablets can produce durable,[link widoczny dla zalogowanych], can use a standard bottle and blister packaging. This technology also includes the activity of flavor components cover. Taking into account the future needs of the market, some of the more advanced instant technology, such as other drug delivery technology to improve the release and bioavailability to improve technologies in order to provide greater treatment of instant technology products. Benefits. The following table lists some current development / original newly listed companies BiovailCardinaHealthCIMALabsEUrandJ & JKVPharmsSchwarzlrusViatris Yamanouchi common name / trade name lorazepam (lorazepam) / FlashDoseparoxetine (paroxetine) / FlashDose8umatriptan (sumatriptan), / Bim'ailzolpidemtartrate (Zolpidem tartrate Tanzania) / FlashDoseapomorphine (apomorphine) / Zydisdomperidone (domperidone) / Zydisfamotidine (famotidine) / Zydisloperamide (loperamide) / Zydislorazepam (lorazepam) / Zydisloratadine (loratadine) / Zydisolanzapine (Austria mirtazapine) / Zydisondansetron (ondansetron) / Zydisoxazepam (oxazepam) / Zydispiroxicam (piroxicam) / Zydisrizatriptanbenzoate (p Bixente triptans) / Zydisselegiline (selegiline) / Zydisfentany (fentanyl ) / CIMAibuprofen (ibuprofen) / Microcaprisperidone (risperidone) / Quickletshyoscyaminesulfate (if alkaline sulfate cirrhosa) / OraQuickhyoscyaminesulphate (hyoscyamine sulfate) SRSS a 023tramadol (tramadol) / Flashtabfamotidine (famotidine) / wowTabramosetron (Ray Mo granisetron) / WowTabtamsulosin (Tamsulosin), immediate release 05,066 non-development of insulin injection International Diabetes Federation (IDF) data suggest that about 2 million people worldwide suffer from diabetes, and WHO believe that the 2025 number will increase to more than 300 million people. Meanwhile, another 300 million people suffer glucose tolerance, which is a signal of diabetes is approaching. Complications of diabetes include cardiovascular problems (such as heart attack and stroke), blind,[link widoczny dla zalogowanych], diabetic ulcers and amputations. It is predicted that the scale of anti-diabetic products in the market in 2006 will reach 200 billion U.S. dollars. In the development of diabetes in the original pre-clinical development stage company Alkermes preclinical preclinical phase Ⅱ clinical pre-registered listing listing listing listing listing listing listing listing listing listing listing listing listing listing Ⅱ clinical listing up early preclinical phase Ⅱ clinical treatment Listing Listing class anti-migraine hypnotic antiepileptic antidepressant / sedative anti-ulcer antidiarrheal antiemetic antiepileptic Parkinson's disease anti-allergic, antipruritic / anti-inflammatory neurological stability, anti-inflammatory anti-anxiety antidepressant antiemetic solution antiparkinsonian migraine pain anti-inflammatory, analgesic,[link widoczny dla zalogowanych], NSAID neuroleptanalgesia ulcer, inflammation of the gastrointestinal tract / gastrointestinal disease, migraine pain Urology ulcer ulcer antiemetic anti-prostate disease ScripMagazineJan2004, 28 (Zhang Ming Abstract) the total number of drugs increased over the past 8 years 3 times, close to 300. All type 1 and type 2 diabetes need a lot of insulin treatment, but despite aggressive small, pen-shaped device, but injection is still out of favor, so non-injected formulations of insulin market potential is huge. It is not only more acceptable, it can improve compliance, resulting in better treatment and to reduce diabetes-related complications. Received attention in several ways present in the table below, including inhalation, oral tablets, buccal and nasal delivery. Table of non-insulin delivery products developer partners through the inhalation method of Lilly's AIR pulmonary delivery system development phase II clinical trial 25 *